Breakthrough in Ophthalmology
L V Prasad Eye Institute (LVPEI), Hyderabad, has been granted an Australian patent for its innovative cell therapy designed to repair damaged corneas caused by various diseases. This groundbreaking cell-based treatment marks a major advancement in ophthalmology and regenerative medicine.
Unique Cell Composition for Corneal Repair
The patented therapy involves advanced cell compositions consisting of limbal epithelial and stromal cells, offering a promising solution for treating and preventing corneal diseases. It also covers the production methods and therapeutic applications of these cell compositions. Previously, the therapy received a patent from the Patent Office, Government of India, under the Patents Act, 1970, for a period of 20 years. Currently, government-approved clinical trials are underway, requiring further validation before the therapy becomes widely available.
Pioneering Scientists Behind the Innovation
As per the press release, the patent was awarded to Dr. Sayan Basu and Dr. Vivek Singh from LVPEI. Dr. Basu, a corneal surgeon and clinician-scientist, holds the Prof. D Balasubramanian Chair of Eye Research at the Brien Holden Eye Research Centre (BHERC) and directs the Centre for Ocular Regeneration (CORE) at LVPEI. Dr. Singh is a scientist at the Sudhakar and Sreekanth Ravi Stem Cell Biology Laboratory and CORE at LVPEI.
Addressing Corneal Blindness and Scarring
Corneal scarring occurs when the cornea, the eye’s transparent outer layer, becomes opaque due to infections or injuries, leading to vision impairment. Corneal blindness remains a significant cause of blindness, particularly in low- and middle-income countries. The primary treatment option today is corneal transplantation, a complex procedure requiring lifelong management. However, LVPEI’s patented cell therapy provides a viable alternative by utilizing a person’s own or donor corneal stem cells to regenerate a clear and healthy corneal surface.
Potential Impact on Keratoconus Treatment
The therapy also shows promise in treating keratoconus, a progressive condition that causes corneal thinning and distortion, affecting vision. By using this novel therapy, researchers aim to replenish corneal collagen, the essential protein responsible for maintaining corneal structure. This could strengthen the cornea and provide an effective treatment for keratoconus, reducing the need for invasive procedures.
A Global Milestone for Indian Ophthalmic Research
Dr. Singh emphasized that this marks the first Australian patent granted to India for a stromal stem cell-based therapy targeting corneal scars. He highlighted its long-term benefits in providing an affordable and effective treatment for individuals with visual impairments.
“If the clinical trials succeed, this cell-based therapy could revolutionize the treatment of various corneal diseases,” added Dr. Basu.
With continued research and validation, this innovative therapy has the potential to transform eye care, offering hope to millions worldwide.